Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT1 cancer vaccine
- Development stage
- Preclinical
- Lead developer
- Shining Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intramuscular
01
Overview
WT1 cancer vaccine is an experimental immunotherapy being developed by Shining Biotech for the treatment of solid tumors. The vaccine targets the Wilms' Tumor 1 (WT1) antigen, a zinc-finger transcription factor that is highly expressed in a variety of cancers but has limited expression in normal adult tissues. By presenting WT1-derived antigens, the vaccine is intended to stimulate a cytotoxic T-lymphocyte (CTL) response specifically against tumor cells that overexpress WT1. As of 2024, the program is in the preclinical stage of development.
- Other names
- WT1 vaccineWT-1 vaccineWT 1 vaccineWilms' Tumor 1 antigen cancer vaccine
02
Targets
HLA-A*24 (Major histocompatibility complex class I molecule presenting MAGE-A4 peptide)pMHC-I (Peptide–MHC class I complex)WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on WT1 cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT1 cancer vaccine.